A phase i study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: A Gynecologic Oncology Group study

Gynecologic Oncology

Volumn 125, Issue 1, 2012, Pages 54-58

  Gould, Natalie ^a   Sill, Michael W ^b   Mannel, Robert S ^c   Thaker, P H ^d   Disilvestro, Paul ^e   Waggoner, Steve ^f   Yamada, S Diane ^g   Armstrong, Deborah K ^h   Wenzel, Lari ⁱ   Huang, Helen ^b   Fracasso, Paula M ^j   Walker, Joan L ^c  

^a Women's Cancer Center of Nevada   (United States)

^b Buffalo Niagara Enterprise   (United States)

^c UNIVERSITY OF OKLAHOMA   (United States)

^d WASHINGTON UNIVERSITY   (United States)

^e WOMEN AND INFANTS HOSPITAL   (United States)

^f CASE WESTERN RESERVE UNIVERSITY   (United States)

^g UNIVERSITY OF CHICAGO   (United States)

^h JOHNS HOPKINS UNIVERSITY   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j UNIVERSITY OF VIRGINIA   (United States)

more..

Author keywords

Carboplatin; Intraperitoneal chemotherapy; Ovarian cancer; Paclitaxel; Phase I trial

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; PACLITAXEL;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG FATALITY; DRUG TOLERABILITY; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERSENSITIVITY REACTION; HYPOKALEMIA; HYPONATREMIA; INFECTION; MAJOR CLINICAL STUDY; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROTOXICITY; OVARY CARCINOMA; PRIORITY JOURNAL; THROMBOCYTOPENIA; UTERINE TUBE CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FALLOPIAN TUBE NEOPLASMS; FEASIBILITY STUDIES; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INFUSIONS, PARENTERAL; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; PERITONEAL NEOPLASMS;

EID: 84858333131     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.12.417     Document Type: Article

References (19)

1. http://cajournal.org
2. D.S. Alberts, P.Y. Liu, and E.V. Hannigan Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer N Engl J Med 335 1996 1950 1955 (Pubitemid 26428219)
3. M. Markman, B.N. Bundy, and D.S. Alberts Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group J Clin Oncol 19 2001 1001 1007 (Pubitemid 32176274)
4. D.K. Armstrong, B.N. Bundy, and L. Wenzel Intraperitoneal cisplatin and paclitaxel in ovarian cancer N Eng J Med 354 2006 34 43 (Pubitemid 43048949)
5. L. Wenzel, H. Huang, D. Armstrong, J. Walker, and D. Cella Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group study J Clin Oncol 25 2007 437 443 (Pubitemid 350002993)
6. http://ctep.cancer.giv/highlights.ovarian.html
7. H. Mälmstrom, E. Simonsen, and R. Westberg A Phase II study of intraperitoneal carboplatin as adjuvant treatment in early-stage ovarian cancer patients Gynecol Oncol 52 1994 20 25 (Pubitemid 24066847)
8. M. Markman, B. Reichman, and T. Hakes Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancer Gynecol Oncol 50 1993 100 104 (Pubitemid 23235519)
9. K. Fujiwara, M. Markman, and M. Morgan Intraperitoneal carboplatin-based chemotherapy for epithelial ovarian cancer Gynecol Oncol 97 2005 10 15 (Pubitemid 40403668)
10. H.W. Huang, M.F. Brady, D. Cella, and G. Fleming Validation and reduction of FACT/GOG-NTX subscale for platinum/paclitaxel-induced neurologic symptoms: a Gynecologic Oncology Group study Int J Gynecol Cancer 17 2007 387 393 (Pubitemid 46426765)
11. S.G. Arbuck Workshop on phase I design: Ninth NCI EORTC new drug development symposium, Amsterdam, March 12, 1996 Ann Oncol 7 6 1996 567 573 (Pubitemid 26285635)
12. T.R. Fleming One-sample multiple testing procedures for phase II clinical trials Biometrics 38 1982 143 151
13. J.R. Schultz, F.R. Nichol, G.L. Elfring, and S.D. Weed Multiple-stage procedures for drug screening Biometrics 29 1973 293 300
14. J.L. Walker Intraperitoneal chemotherapy for ovarian cancer: 2009 goals Gynecol Oncol 112 2009 430 440
15. Y. Miyagi, K. Fujiwara, and J. Kigawa Intraperitoneal carboplatin may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a mathematical model after intraperitoneal vs. intravenous infusion of carboplatin-A Sankai Gynecology Study Group (SGSG) study Gynecol Oncol 99 2005 591 596 (Pubitemid 41686541)
16. K. Fujiwara, S. Suzuki, and H. Ishikawa Preliminary toxicity analysis of intraperitoneal (IP) carboplatin in combination with intravenous (IV) paclitaxel chemotherapy for patients with carcinoma of the ovary, peritoneum, or fallopian tube Int J Gynecol Cancer 15 2005 426 431 (Pubitemid 40705536)
17. M. Morgan, M. Sill, and K. Fujiwara A Phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube and primary peritoneal carcinoma: a Gynecologic Oncology Group study Gynecol Oncol 121 2011 264 268
18. K. Fujiwara, N. Sakuragi, and S. Suzuki First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up Gynecol Oncol 90 2003 637 643
19. L. Wagner, L. Wenzel, E. Shaw, and D. Cella Patient-reported outcomes in phase II cancer clinical trials: lessons learned and future directions J Clin Oncol 25 2007 5058 5062 (Pubitemid 350237601)